The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...

Still riding the high of last year’s twice-yearly HIV PrEP approval of lenacapavir as Yeztugo, Gilead Sciences is approaching ...

Charles River Laboratories has struck a $510 million deal to buy a non-human primate provider, furthering efforts to ...

Looking to usher in a more “predictable” year in 2026, Illumina is working with officials in China as it remains on the ...

With a White House drug pricing deal done and dusted and the threat of tariffs ameliorated, Sanofi is enjoying more clarity from the U.S. government now than the same time last year. But several ...

The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since being founded last year, Caldera has already taken the therapy, dubbed CLD-423, ...

It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. | It’s been a subdued—albeit ...

After a busy first day featuring headlines from a who's who of leading biopharma companies, the J.P. | The J.P. Morgan ...

While the 2026 J.P. Morgan Healthcare Conference has thus far failed to yield any major M&A deals for the industry, Medtronic believes the time is ripe for buyouts. | While the 2026 J.P. Morgan ...

After a year of significant disruption at Novo Nordisk, the company's R&D chief has told Fierce Biotech that the deal-hungry ...

The twisting journey of Pretzel Therapeutics’ top brass appears to have come full circle, with the biotech subsuming the very ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...